Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease

Bone Marrow Transplantation volume 34, pages 987–994 (2004)Cite this article

Summary:

Prior studies suggest that depletion of CD8+ T cells from donor bone marrow or donor lymphocyte infusions can reduce graft-versus-host disease (GVHD) without compromising graft-versus-leukemia. We explored CD8 depletion in patients undergoing matched related donor (MRD, n=25) and unrelated donor (URD, n=16) peripheral blood stem cell transplantation following myeloablative conditioning with cyclophosphamide (60 mg/kg/day i.v. × 2) and total body irradiation (200 cGy × 7 fractions). Ex vivo incubation of mobilized donor peripheral blood cells with anti-CD8 antibody coated high-density microparticles removed 99% of CD8+ cells. The median number of CD8+ cells infused was 3.9 × 105 cells/kg (2.2 × 105 in MRD, and 8.1 × 105 in URD patients). Post transplant immune suppression included tacrolimus in the MRD cohort, and tacrolimus plus mini-methotrexate (5 mg/m2 days +1, 3, 6, 11) in the URD cohort. All 41 patients engrafted. Grade 2–4 acute GVHD incidence was 61% (44% MRD, 88% URD). Chronic GVHD incidence was 50% (48% MRD, 55% URD). Relapse incidence was 4.9%. Estimated event-free and overall survival rates were 65 and 63%, respectively, at 1 year and 56 and 57%, respectively, at 2 years. There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Ho VT, Soiffer RJ . The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192–3204.

    Article  CAS  PubMed  Google Scholar 

  2. Zutter MM, Martin PJ, Sale GE et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.

    CAS  PubMed  Google Scholar 

  3. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–814.

    Article  CAS  PubMed  Google Scholar 

  4. Gerritsen EJ, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377–382.

    CAS  PubMed  Google Scholar 

  5. Kernan NA, Bordignon C, Heller G et al. Graft failure after T-cell-depleted leukocyte antigen identical marrow transplants for leukemia: I. analysis of risk factors and results of secondary transplants. Blood 1989; 74: 2227–2236.

    CAS  PubMed  Google Scholar 

  6. Mitsuyasu RT, Champlin RE, Gale RP et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 1986; 105: 20–26.

    Article  CAS  PubMed  Google Scholar 

  7. Marmont A, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120–2130.

    CAS  PubMed  Google Scholar 

  8. Champlin RE, Passweg JR, Zhang MJ et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996–4003.

    CAS  PubMed  Google Scholar 

  9. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337–4343.

    CAS  PubMed  Google Scholar 

  10. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671–3680.

    CAS  PubMed  Google Scholar 

  11. Soiffer RJ, Alyea EP, Hochberg E et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625–632.

    Article  PubMed  Google Scholar 

  12. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 1994; 57: 82–87.

    Article  CAS  PubMed  Google Scholar 

  13. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  14. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995–1003.

    Article  CAS  PubMed  Google Scholar 

  15. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702–3709.

    CAS  PubMed  Google Scholar 

  16. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  PubMed  Google Scholar 

  17. Gray R . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988; 16: 1141–1154.

    Article  Google Scholar 

  18. Kaplan G, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  19. Roux E, Helg C, Dumont-Girard F et al. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984–3992.

    CAS  PubMed  Google Scholar 

  20. Soiffer RJ, Bosserman L, Murray C et al. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood 1990; 75: 2076–2084.

    CAS  PubMed  Google Scholar 

  21. Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93: 467–480.

    CAS  PubMed  Google Scholar 

  22. Schwartz J, Buchbarker D, Griffin D et al. Single agent tacrolimus for prophylaxis of acute graft-versus host disease after related allogeneic peripheral blood stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2003; 9: 97 (abstr 109).

    Article  Google Scholar 

  23. Martin PJ . Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703–712.

    Article  CAS  PubMed  Google Scholar 

  24. Martin PJ, Rowley SD, Anasetti C et al. A phase I–II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999; 94: 2192–2199.

    CAS  PubMed  Google Scholar 

  25. Bertheas MF, Lafage M, Levy P et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 1991; 78: 3103–3106.

    CAS  PubMed  Google Scholar 

  26. Mackinnon S, Barnett L, O'Reilly RJ . Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 3409–3416.

    CAS  PubMed  Google Scholar 

  27. Champlin R, Ho W, Gajewski J et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418–423.

    CAS  PubMed  Google Scholar 

  28. Alyea E, Weller E, Schlossman R et al. T cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft versus myeloma effect. Blood 2001; 98: 934–939.

    Article  CAS  PubMed  Google Scholar 

  29. Baron F, Baudoux E, Frere P et al. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. J Hematother Stem Cell Res 2002; 11: 301–314.

    Article  PubMed  Google Scholar 

  30. Jansen J, Hanks S, Akard L et al. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 271–278.

    CAS  PubMed  Google Scholar 

  31. Cosmi L, Liotta F, Lazzeri E et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003; 102: 4107–4114.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by The Ted and Eileen Pasquarello Leukemia Research Fund and NIH Grants AI29530 and HL70149-01A1. VTH is a recipient of the ASH Clinical Fellow Scholar Award. RJS is a recipient of the LLSA Scholar for Clinical Research Career Development Award-# 2020-00.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA, USA

    V T Ho, E P Hochberg, C Cutler, S J Lee, D C Fisher, G Kao, H Daley, J Levin, E P Alyea, J H Antin & R J Soiffer

  2. Department of Biostatistics, Dana Farber Cancer Institute, Boston, MA, USA

    H T Kim & S Li

  3. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

    V T Ho, E P Hochberg, C Cutler, S J Lee, D C Fisher, E Milford, E P Alyea, J H Antin & R J Soiffer

  4. Department of Radiation Therapy, Brigham and Women's Hospital, Boston, MA, USA

    A Ng & P Mauch

Authors
  1. V T Ho
    View author publications

    Search author on:PubMed Google Scholar

  2. H T Kim
    View author publications

    Search author on:PubMed Google Scholar

  3. S Li
    View author publications

    Search author on:PubMed Google Scholar

  4. E P Hochberg
    View author publications

    Search author on:PubMed Google Scholar

  5. C Cutler
    View author publications

    Search author on:PubMed Google Scholar

  6. S J Lee
    View author publications

    Search author on:PubMed Google Scholar

  7. D C Fisher
    View author publications

    Search author on:PubMed Google Scholar

  8. E Milford
    View author publications

    Search author on:PubMed Google Scholar

  9. G Kao
    View author publications

    Search author on:PubMed Google Scholar

  10. H Daley
    View author publications

    Search author on:PubMed Google Scholar

  11. J Levin
    View author publications

    Search author on:PubMed Google Scholar

  12. A Ng
    View author publications

    Search author on:PubMed Google Scholar

  13. P Mauch
    View author publications

    Search author on:PubMed Google Scholar

  14. E P Alyea
    View author publications

    Search author on:PubMed Google Scholar

  15. J H Antin
    View author publications

    Search author on:PubMed Google Scholar

  16. R J Soiffer
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to V T Ho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ho, V., Kim, H., Li, S. et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 34, 987–994 (2004). https://doi.org/10.1038/sj.bmt.1704690

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704690

Keywords

This article is cited by

Search

Advanced search

Quick links